Pathogenic variants in DPM1 and DPM2 are associated with muscle–eye–brain (MEB) disease, whereas DPM3 variants have mostly been reported in patients with isolated muscle disease—dystroglycanopathy. Here, DPM2 is linked to neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.